Fig. 2: GLUD2 mutation exacerbates nigral cell death in MPTP-treated mice.
From: Functional validation of a human GLUD2 variant in a murine model of Parkinson’s disease
a Immunohistochemical staining of TH-positive cells in the SNpc in AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars, 100 µm). The ellipses in the middle column of (a) show the boundaries of the SNpc, and the middle-column boxes denote the areas that are expanded in the right-hand columns. n = 8. b Immunofluorescent staining of GFP and TH in the SNpc of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars, 40 µm). c Expression levels of GDH2, GDH1, and GFAP in the SN of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups were determined by western blotting. The bottom band (~55 KD) in the GDH2 blot is non-specific. n = 6. d Immunofluorescent staining of GFP and GFAP in the SNpc of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars, upper, 40 µm; lower, 10 µm). Results are expressed as the mean ± SEM. **p < 0.01 vs. AAV-GFP group or untreated U251 cells. #p < 0.05 vs. MPTP + AAV-GFP or MPP+ group. &&p < 0.01 vs. MPP+ + GLUD2 group. Statistical significance was determined by one-way ANOVAs and Tukey tests for post-hoc comparisons.
